Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences, Inc. (NASDAQ: SAVA) was one of Monday’s biggest winners after the company reported midstage results from its clinical study in Alzheimer’s disease (AD).

How Cassava Sciences Could Be Pioneering A Groundbreaking Alzheimer’s Treatment

Shares of Cassava Sciences Inc. SAVA, +81.92% skyrocketed 85.7% on massive volume Monday, after the drug maker's upbeat update on its Alzheimer's disease treatment prompted Maxim analyst Jason McCarthy to turn bullish.

Cassava Sciences rockets on heavy volume after Alzheimer's drug trial results prompts analyst upgrade

Cassava Sciences Inc (NASDAQ: SAVA) shares were nearly doubling in value Monday following the release of a clinical trial readout.

Cassava Sciences Rips Higher After Alzheimer's Drug Meets Study Goals

Alzheimer’s  Patients in Drug Groups Showed Statistically Significant Improvements in Biomarkers of Disease Compared to Placebo Group (P

Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in  Patients with Alzheimer’s Disease

AUSTIN, Texas, Sept.  11, 2020  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Monday, September 14th at 8:30 a.m. Eastern Time. 

Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ET

AUSTIN, Texas, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present a corporate overview at H.C. Wainwright’s 22nd Annual Global Investment Conference.

Cassava Sciences to Present at H.C. Wainwright’s 22nd Annual Global Investment Conference

Patent Protection Runs Through Year 2037, Plus Extensions Patent Protection Runs Through Year 2037, Plus Extensions

Cassava Sciences Announces New Patent Grant

- Sumifilam Is First of a New Class of Drugs That Target Filamin Proteins -

Cassava Sciences Announces Lead Drug Candidate  PTI-125 Is Assigned the Chemical Drug Name ‘sumifilam’ by USAN

- Final Clinical Results of a Phase 2b Study i n Alzheimer’s Disease  with Lead Drug Candidate, PTI-125,  Expected to be Announced September 2020 -

Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review

Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%

AUSTIN, Texas, July  09, 2020  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that its lead neuroscientist, Lindsay H. Burns, PhD, will give a keynote presentation at the Biomarkers  for Alzheimer’s Disease Summit, a virtual conference, on July 15, 2020. Dr. Burns’ talk will focus on SavaDx, the Company’s investigational diagnostic to detect Alzheimer’s disease with a simple blood test.

Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific Conference

AUSTIN, Texas, June  16, 2020  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes, effective after the close of the U.S. markets on Friday, June 26, 2020. These indexes provide institutional investors and other market participants with exposure to the performance of certain segments of the U.S. stock market.

Cassava Sciences Added to Russell Indexes and Provides Phase 2b Study Update

Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Cassava Sciences (SAVA) in Focus: Stock Moves 8.5% Higher

Cassava Sciences Inc (NASDAQ: SAVA) shares have tumbled to their lowest level since mid-December 2019 after the company issued an adverse clinical readout.

Why Nano-Cap Biotech Cassava Is Losing 75% Of Its Market Cap

Shares of Cassava Sciences Inc. SAVA, -72.02% tumbled 73.2% in trading on Friday after the company said its investigational Alzheimer's disease treatment failed a mid-stage trial.

Cassava stock falls on failed Alzheimer's study

-  Study  Showed High Variability in Levels of CSF Biomarkers Over 28 Days  -

Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint

Alexion Pharma

Avid Technology

B2Gold

CURO Group Hlds

If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.

Add Value to Your Portfolio With 5 High Earnings Yield Picks

- Grant Will Support an On-going Clinical Evaluation of Lead Investigational Drug PTI-125 in Alzheimer’s Disease -

Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health

Approximately 100 Study Participants Will Receive PTI-125 For 12 Months Approximately 100 Study Participants Will Receive PTI-125 For 12 Months

Cassava Sciences Announces Initiation of an Open-Label Study to Evaluate PTI-125 in Patients with Alzheimer’s Disease

AUSTIN, Texas, March  19, 2020  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced clinical updates and business progress across its pipeline of product candidates under development.

Cassava Sciences Announces Clinical Update and Business Progress Across Neuroscience Pipeline

During the Q4 investors' call, Cassava Sciences (SAVA) is likely to provide an update on its lead candidate PT-125, which is being developed for the treatment of Alzheimer's disease.

What Lies Ahead for Cassava Sciences (SAVA) in Q4 Earnings?

AUSTIN, Texas, Feb.  11, 2020  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, published results from the Company’s Phase 2a study demonstrating that its lead drug candidate, PTI-125, reduced biomarkers of disease in Alzheimer’s patients.

Cassava Sciences Announces Phase 2a Study of PTI-125 Published in  The Journal of Prevention of Alzheimer’s Disease (JPAD)

Top-Line Results Expected Mid-year 2020 Top-Line Results Expected Mid-year 2020

Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease

Cassava Sciences: An Investment Opportunity With Some Volatile Periods But A Net Upside

Agile Therapeutics

Air Industries Group

Journey Medical Corp

Microbot Medical

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

News for Cassava Sciences Inc Stock (SAVA)